AVGEMSI
GEMCITABINE HYDROCHLORIDE
Approval overview AVGEMSI is listed in Drugs@FDA under application 219920 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient GEMCITABINE HYDROCHLORIDE Form and strength SOLUTION;INTRAVENOUS - EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML) Sponsor AVYXA HOLDINGS Submission history Latest submission status date: 2025-06-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview AVGEMSI is listed in Drugs@FDA under application 219920 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient GEMCITABINE HYDROCHLORIDE Form and strength SOLUTION;INTRAVENOUS - EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML) Sponsor AVYXA HOLDINGS Submission history Latest submission status date: 2025-06-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.